In vitro and in vivo evaluation of a bondable compact for the prolonged delivery of triamcinolone acetonide to the oral cavity in patients with lichen planus.
Compacts weighing 40 mg and containing triamcinolone acetonide 70-90% and polyhydroxybutyric acid (PHB) 30-10% or poly (DL-lactic acid) 20% with a diameter of 5 mm were bonded onto the side-wall of molar teeth. In vitro dissolution studies showed the compacts to release 12% of drug in 30 days with an initial burst effect. Drug loading or polymer matrix type had little effect. In vivo studies in dogs showed that compacts containing 80% drug in PHB produced salivary levels of triamcinolone acetonide for 30 days. When evaluated in five patients with lichen planus resistant to conventional therapy, these compacts produce a slight clinical improvement in three subjects. Differential scanning calorimetry studies confirmed that the drug and polymer were present as a physical mix in these compacts.
Deasy
P B
PB
Collins
A E
AE
Burke
F M
FM
Shanley
D B
DB
D000293:Adolescent; D000328:Adult; D000818:Animals; D003692:Delayed-Action Preparations; D004285:Dogs; D006801:Humans; D008010:Lichen Planus / Q000188:drug therapy*; D008875:Middle Aged; D000091402:Prohibitins; D014222:Triamcinolone Acetonide / Q000008:administration & dosage* / Q000627:therapeutic use
D003692:Delayed-Action Preparations; C000717328:PHB protein, human; D000091402:Prohibitins; D014222:Triamcinolone Acetonide